About Us

Creating new hope, and improving patient outcomes, in infectious diseases and cancer

The GEN-Y Team

GEN-Y Biologics was formed in 2020 to license, productise and take to market superior antibody technologies derived from state-of-the-art technological platforms developed with the National University of Singapore’s highly prestigious Life Sciences Institute.

Their unique antibody discovery platform for fully human antibodies, together with advanced antibody and protein engineering, provides a pipeline of highly specific biologics for therapeutic and diagnostic use.


What We Do

Fully Human Antibodies

    • Our technology employs a powerful method to screen human memory B cells from convalescent patients
    • Using a blend of bioinformatics, massive parallel sequencing and high throughput functional assays, we identify fully human monoclonal antibodies for research, therapy or diagnostics
    • Our antibodies are expressed in high-yielding, industry standard mammalian expression platforms CHO and HEK

Advanced Protein Engineering

    • Our experienced protein engineering team at NUS designs constructs, expressing these in-house, in industry standard mammalian HEK/CHO cells. After purifying and formulating, these are tested for functional activity before incorporating into our prototype build. We work with partners to GMP manufacture the final product.

Fully Human Antibody Discovery

Scientific Team

Assoc Prof Paul MacAry, PhD

Founding Scientist & Senior Scientific Advisor

  • Associate Professor and Director, Life Sciences Institute, National University of Singapore
  • Co-Chair & Co-Director, Singapore-Hebrew University of Jerusalem Research Alliance
  • Expert in Antibody Technologies & Infectious Diseases
  • PhD King’s College London

Prof William Haseltine, PhD

 Scientific Advisor

  • Chairman and President of ACCESS Health International
  • Expert in Infectious Diseases (HIV/AIDS, COVID-19)
  • Founder of >7 Biotech Companies
  • Former Professor, Harvard Medical School
  • Former Presidential Advisor, HIV/AIDS, to US and French Governments
  • PhD Harvard University

Prof Jeffrey Almond, PhD FMedSci

Scientific Advisor

  • Visiting Professor of Microbiology, University of Oxford
  • Chairman, Virion Health
  • Science Advisory Board Member National Institute for Biological Standards and Control, UK
  • Work-Group Chair, UK Government Vaccine Network
  • Former Head of Vaccine R&D, Sanofi Pasteur
  • Former Professor, University of Reading
  • PhD University of Cambridge

The GEN-Y Management Team

Graham Almond


  • Managing Director, Lumicara Pte Ltd
  • Former Vice-President SE Asia, Global Operations, Sanofi
  • Former SEA PhRMA head
  • BSc University of Manchester

Mary Kozma

Product Development & Manufacturing 

  • Former Manager NUS, Institute of Life Sciences Antibody Engineering Programme
  • 30+ years research and laboratory management experience
  • Researcher at Imperial College, University of London; Royal Free Hospital Medical School, University of London; Imperial Cancer Research Fund, London
  • BSc University of Edinburgh

Board of Directors

Kenneth Tan

Co-Founder, Chairman of the Board and Acting CFO

  • Managing Partner & Managing Director of Southern Capital
  • Co-Founder and EVP of Cassis International
  • Former Assistant VP at GIC
  • BA (First Class Honours), Cambridge University

Xiang Liang (XL) Lin


  • Deputy CEO, ESCO Lifesciences Group
  • Founding CEO, ESCO Aster
  • Early Stage Biotech Investor
  • BSc University of Sydney

Suong Hong Nguyen

Co-Founder, Executive Director and CBO

  • Managing Director of Victory Global Holdings
  • Founding member of Asia Capital Enterprises, GC Millennium Group, Starise Investments and Cathay Investment Fund
  • Established Equity Derivatives across European Markets at Morgan Stanley
  • MBA Harvard University, Post-doctorate INSEAD